14-06-2018
Hailshadow / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Initiative for Medicines, Access & Knowledge, I-MAK, patent, Sovaldi, Gilead, generics, hepatitis C, pharmaceuticals, PTAB
PTAB blocks Qiagen’s bid to invalidate diagnostics patent
20-07-2020
PTAB shoots down tenth I-MAK Gilead challenge
24-07-2018
MSF challenges Gilead patent in China
20-06-2018
Non-profit group continues battle against Gilead patents
08-12-2017
Public interest group challenges ‘unmerited’ Gilead patents
26-10-2017
